Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ poses questions on VTE prophylaxis

This article was originally published in The Gray Sheet

Executive Summary

Agency for Healthcare Research and Quality is taking comments through June 4 on the comparative effectiveness of venous thromboembolism (VTE) prophylaxis in orthopedic surgery. Key questions posted online May 7 address the overall baseline risk of VTE and bleeding outcomes in patients undergoing major orthopedic surgery such as total hip or knee replacement or hip fracture surgery. AHRQ also plans to look at what patient characteristics can predict or differentiate risk of VTE and bleeding, whether risk can be detected by venography or ultrasound, and how preventive treatments impact patient outcomes
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028867

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel